Recalibrating intellectual property rights to enhance translational research collaborations
- PMID: 22357536
- DOI: 10.1126/scitranslmed.3003490
Recalibrating intellectual property rights to enhance translational research collaborations
Abstract
Multisectoral collaborative models for drug and therapeutic research and development (R&D) are emerging, requiring a recalibration of how intellectual property rights (IPRs) are used. Although these models appear promising, little study has been conducted on the optimal blend of sharing and exclusion as mediated through the proactive use or nonuse of IPRs. This Commentary is a call for a combination of theoretical and empirical analyses to build a comprehensive understanding of the interplay between formal IP laws, institutions that administer and manage IPRs, and the use of IPRs in practice to better construct and manage collaborations. Such analyses require outcome metrics formulated to measure the success of therapeutic outcomes and to capture the complexity of a highly networked R&D environment.
Similar articles
-
Access to stem cells and data: persons, property rights, and scientific progress.Science. 2011 Feb 11;331(6018):725-7. doi: 10.1126/science.1201382. Science. 2011. PMID: 21311015
-
Human-tissue-related inventions: ownership and intellectual property rights in international collaborative research in developing countries.J Med Ethics. 2008 Mar;34(3):171-9. doi: 10.1136/jme.2006.019612. J Med Ethics. 2008. PMID: 18316458
-
Intellectual property rights, standards and data exchange in systems biology: Reflections from the IP Expert Meeting at the University of Luxembourg, 8-9 October 2015, ERASysAPP - ERA-Net for Systems Biology Applications.Biotechnol J. 2016 Dec;11(12):1477-1480. doi: 10.1002/biot.201600109. Biotechnol J. 2016. PMID: 27966844
-
Translational strategies for the development of a wound healing technology (idea) from bench to bedside.Methods Mol Biol. 2013;1037:567-81. doi: 10.1007/978-1-62703-505-7_33. Methods Mol Biol. 2013. PMID: 24029959 Review.
-
The biomarker is not the end.Drug Discov Today. 2011 Oct;16(19-20):878-83. doi: 10.1016/j.drudis.2011.08.011. Epub 2011 Aug 24. Drug Discov Today. 2011. PMID: 21888986 Review.
Cited by
-
Prioritising and incentivising productivity within indicator-based approaches to Research Impact Assessment: a commentary.Health Res Policy Syst. 2023 Dec 18;21(1):136. doi: 10.1186/s12961-023-01082-7. Health Res Policy Syst. 2023. PMID: 38110938 Free PMC article.
-
Patents and misplaced angst: lessons for translational stem cell research from genomics.Cell Stem Cell. 2013 May 2;12(5):508-12. doi: 10.1016/j.stem.2013.04.015. Cell Stem Cell. 2013. PMID: 23642360 Free PMC article.
-
Public-Private Partnerships in Cloud-Computing Services in the Context of Genomic Research.Front Med (Lausanne). 2017 Jan 20;4:3. doi: 10.3389/fmed.2017.00003. eCollection 2017. Front Med (Lausanne). 2017. PMID: 28164085 Free PMC article. Review.
-
21(st) Century Cures Act: An Act of Cure or Diagnosis?Rejuvenation Res. 2015 Aug;18(4):295-8. doi: 10.1089/rej.2015.1757. Rejuvenation Res. 2015. PMID: 26291241 Free PMC article. No abstract available.
-
More Haste, Less Speed: Could Public-Private Partnerships Advance Cellular Immunotherapies?Front Med (Lausanne). 2017 Aug 16;4:134. doi: 10.3389/fmed.2017.00134. eCollection 2017. Front Med (Lausanne). 2017. PMID: 28861415 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
